Show simple item record

dc.contributor.authorTymms, Kathleen
dc.contributor.authorLittlejohn, Geoff
dc.contributor.authorGriffiths, Hedley
dc.contributor.authorde Jager, Julien
dc.contributor.authorBird, Paul
dc.contributor.authorJoshua, Fred
dc.contributor.authorNash, Peter
dc.contributor.authorHandel, Malcolm
dc.contributor.authorMcManus, Hamish
dc.contributor.authorButcher, Belinda E
dc.contributor.authorYoussef, Peter
dc.date.accessioned2020-01-17T01:22:59Z
dc.date.available2020-01-17T01:22:59Z
dc.date.issued2018
dc.identifier.issn0770-3198
dc.identifier.doi10.1007/s10067-018-4105-3
dc.identifier.urihttp://hdl.handle.net/10072/390570
dc.description.abstractThe aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) for patients with inflammatory rheumatic disease newly initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARD). This was a retrospective cohort study that extracted data for new users of TNFi between 1 August 2010 and 31 August 2016 from the Australian Optimising Patient outcome in Australian RheumatoLogy (OPAL) registry. Patients were 1:1 propensity-score matched with golimumab based on their age, sex, year of index, C-reactive protein level, baseline treatment combination and disease. Treatment persistence was calculated. Data from 3749 patients were extracted (adalimumab n = 1518; certolizumab n = 298; etanercept n = 1068; golimumab n = 865). The mean (SD) ages of patients were 51.7 (14.2) years for adalimumab, 53.7 (14.0) years for certolizumab, 52.8 (14.3) years for etanercept and 52.3 (14.6) years for golimumab, with disease durations 7.7 (10.5), 8.8 (9.2), 8.1 (10.4) and 7.3 (9.7) years, respectively. Two thirds of the patients were women. There was no significant difference in treatment persistence by treatment in the overall population (adalimumab 33.6 [95% CI 28.6–40.7], certolizumab 24.8 [95% CI 21.3–42.1], etanercept 27.6 [95% CI 23.4–36.5], golimumab 30.3 [95% CI 23.26–36.5]; months, p = 0.545), or in the propensity score-matched population. No safety signals were detected. In this real-world biologic-naïve Australian inflammatory rheumatic disease cohort treated with subcutaneous TNF inhibitors during the period 2010–2016, there was no difference in treatment persistence between agents.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofpagefrom1617
dc.relation.ispartofpageto1623
dc.relation.ispartofissue6
dc.relation.ispartofjournalClinical Rheumatology
dc.relation.ispartofvolume37
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3202
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsRheumatology
dc.subject.keywordsAnkylosing spondylitis
dc.subject.keywordsMedication persistence
dc.titleTreatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationTymms, K; Littlejohn, G; Griffiths, H; de Jager, J; Bird, P; Joshua, F; Nash, P; Handel, M; McManus, H; Butcher, BE; Youssef, P, Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors, Clinical Rheumatology, 2018, 37 (6), pp. 1617-1623
dcterms.dateAccepted2018-04-10
dc.date.updated2020-01-17T01:21:46Z
gro.hasfulltextNo Full Text
gro.griffith.authorNash, Peter


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record